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ABSTRACT
APE1 (Ref-1) is an essential human protein involved
in DNA damage repair and regulation of transcrip-
tion. Although the cellular functions and biochem-
ical properties of APE1 are well characterized, the
mechanism involved in regulation of the cellular
levels of this important DNA repair/transcriptional
regulation enzyme, remains poorly understood.
Using an in vitro ubiquitylation assay, we have
now purified the human E3 ubiquitin ligase UBR3
as a major activity that polyubiquitylates APE1
at multiple lysine residues clustered on the
N-terminal tail. We further show that a knockout of
the Ubr3 gene in mouse embryonic fibroblasts leads
to an up-regulation of the cellular levels of APE1
protein and subsequent genomic instability. These
data propose an important role for UBR3 in the
control of the steady state levels of APE1 and con-
sequently error free DNA repair.
INTRODUCTION
Genome instability is the major cause of many human
diseases, including cancer. One of the major sources of
genome instability is the loss of a DNA base due to hydro-
lytic attack of the glycosylic bond linking DNA bases to
the sugar phosphate backbone of the DNA molecule (1).
These abasic sites (apurinic/apyrimidinic, AP sites) in
DNA can also arise as an intermediate product during
excision repair of various DNA base lesions. It has been
estimated that every single human cell repairs about
10000 AP sites per day (2) and this highlights the import-
ance of the proteins involved in the repair of this cytotoxic
and mutagenic lesion. Human AP endonuclease-1 (APE1,
also known as Ref-1) initiates repair of AP sites by
incising the phosphodiester bond 50 to the AP site and
generating a DNA single-strand break (SSB) containing
a5 0-sugar phosphate residue (3,4). This SSB is further
repaired by DNA polymerase b and XRCC1–DNA
ligase IIIa complex. DNA polymerase b removes the
50-sugar phosphate residue and adds one undamaged nu-
cleotide into the repair gap. Finally, XRCC1–DNA ligase
IIIa complex seals the DNA ends thus accomplishing the
repair process (5). Although being a small protein
(36kDa), APE1 has multiple other enzymatic activities,
including 30-phosphatase, 30-phosphodiesterase and 30-t o
50-exonuclease activities speciﬁc for internal nicks and
gaps in DNA (6). It has also been shown to catalyse the
release of 30-phosphoglycolate moieties that block the
repair of DNA SSBs (7–10). All these enzymatic activities
of APE1 are important for the repair of DNA lesions
induced by oxidative stress and ionising radiation.
In addition, APE1 has an important role as a reductive
activator of a number of transcription factors, including
p53, AP-1, NF-iB and HIF-1a, in response to oxidative
stress (11).
APE1 is known to be absolutely required for cellular
survival since deletion of APE1 in mice is embryonic
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not been established, again pointing to a critical role for
APE1. Down-regulation of APE1 by RNA interference
(15,16) and the generation of conditional Ape1 null mice
(16) conﬁrmed that AP endonuclease activity is essential
for mammalian cell viability and plays a central role in
endogenous and induced DNA damage processing.
Consequently, controlling the cellular levels of APE1
protein is very important as both over- or under-
expression of APE1 leads to genomic instability (17–19)
and is frequently found in cancer cells (11,20–23) and
neurological disorders [(24) and references within].
We have previously demonstrated that the cellular
amounts of DNA polymerase b and XRCC1–DNA
ligase IIIa, involved in repair of SSBs generated by
APE1, are tuned to the amount of DNA damage
through regulated proteasomal degradation. This is
controlled by the E3 ubiquitin ligases Mule, CHIP and
the DNA damage signalling protein and tumour suppres-
sor ARF (25,26). However the mechanism controlling
APE1 levels is unknown. Assuming that APE1 levels are
also controlled by ubiquitylation, we ﬁrst demonstrated
the existence of ubiquitylated APE1 in human cells and
then developed an in vitro ubiquitylation assay for APE1.
Using this assay, we puriﬁed UBR3 as the major human
E3 ubiquitin ligase targeting APE1 for ubiquitylation, and
demonstrate that UBR3 controls the cellular levels of
APE1 and is required for genome stability.
MATERIALS AND METHODS
Antibodies
Polyclonal APE1 antibodies were puriﬁed as described
(27). APE1 mouse monoclonal antibodies for identiﬁca-
tion of mouse APE1 (APEX) were purchased from Abcam
(Cambridge, UK). ARF and 53BP1 antibodies were
purchased from Bethyl Laboratories (Montgomery,
USA), tubulin antibodies were from Sigma-Aldrich
(Gillingham, UK), Mdm2 antibodies were from Santa
Cruz (California, USA) and g-H2AX antibodies were
from Millipore (Watford, UK). Actin, hsp70 and ubiqui-
tin antibodies were purchased from Abcam (Cambridge,
UK). UBR3 antibodies were puriﬁed as recently
described (28).
Plasmids and proteins
Ubiquitin, E1 and E2 enzymes were purchased from
Boston Biochemicals (Cambridge, USA). pET14b
plasmid encoding human APE1 protein was kindly
provided by Prof. Hickson and APE1 mutants were con-
structed using the ‘QuikChange’ protocol (Stratagene,
Amsterdam, Holland) and conﬁrmed by sequencing.
Human histidine-tagged APE1 was puriﬁed by HisTrap
HP column chromatography (GE Healthcare, Little
Chalfont, UK). Plasmid encoding mouse APE1 protein
(APEX) was kindly provided by Dr Nakabeppu and the
Apex gene was re-cloned into pCMV3Tag3a plasmid
(Agilent Technologies, Stockport, UK). N-terminal
FLAG-tagged mouse UBR3 (UBR3) was expressed in
Saccharomyces cerevisiae SC295 (MATa, GAL4 GAL80
ura3-52, leu2-3,112 reg1-501 gal1 pep4-3) from the PADH1
promoter in a high copy vector as described previously
(28). To purify UBR3 protein, the yeast lysate containing
UBR3 was mixed with anti-Flag M2 agarose beads
(Sigma, Gillingham, UK) and after washing the beads,
the bound UBR3 protein was eluted using FLAG
peptide-containing elution buffer (200mg/ml). Puriﬁed
UBR3 protein was dialyzed against PBS, concentrated
and stored at  80 C until required.
Establishment and immortalization of Ubr3
 /  mouse
embryonic ﬁbroblasts
Construction and characterization of Ubr3
 /  mouse was
recently described (28). Primary mouse embryonic ﬁbro-
blasts (MEFs) were established from wild-type and
Ubr3
 /  embryos at E13.5 in the 129SvImJ/C57BL/6
background as previously described (29). Immortalized
MEFs were established from primary MEFs by repeated
cell cultures over  2 months ( 1.5 10
6 cells onto a
10cm
2 plate every 3–5 days).
Whole-cell extracts
Whole-cell extracts were prepared by Tanaka’s method
(30). Brieﬂy, cells were resuspended in one packed cell
volume of buffer containing 10mM Tris–HCl (pH 7.8),
200mM KCl, 1mg/ml of each protease inhibitor (pepstatin,
aprotinin, chymostatin and leupeptin), 1mM DTT and
1mM PMSF. Two packed cell volumes of buffer contain-
ing 10mM Tris–HCl (pH 7.8), 600mM KCl, 40% glycerol,
0.1mM EDTA and 0.2% Nonidet P-40 was then added
and mixed thoroughly before rocking the cell suspension
for 2h at 4 C. The cell lysate was then centrifuged at
40000rpm at 4 C for 20min and the supernatant was col-
lected, aliquoted and stored at  80 C.
Cell fractionation
Cell fractionation was performed as recently described
(31). Brieﬂy, cell pellets were resuspended in two packed
cell volumes of buffer containing 20mM Tris–HCl pH 7.4,
2.5mM MgCl2, 0.5% (v/v) Nonidet P-40, 1mM PMSF,
1mM DTT and 1mg/ml each of aprotinin, pepstatin,
chymostatin and leupeptin, and incubated on ice for
10min. Following centrifugation at 10000rpm for 2min,
the supernatant containing cytoplasmic proteins (C) was
collected. The nuclear pellet was similarly extracted with
two packed cell volumes of buffer containing 20mM Tris–
HCl pH 8.0, 0.5M KCl, 1mM EDTA, 0.75% (v/v) Triton
X-100, 10% (v/v) glycerol, 1mM PMSF, 1mM DTT and
1mg/ml each of aprotinin, pepstatin, chymostatin and
leupeptin and the supernatant containing nuclear
proteins (N) was collected. For identiﬁcation of
ubiquitylated APE1 bands from HeLa cells, 1mM NEM
was also added to each of the buffers prior to extractions.
Western blots
Western blots were performed by standard procedure as
recommended by the vendor (Novex, San Diego, USA).
Blots were visualized using the Odyssey image analysis
system (Li-cor Biosciences, Cambridge, UK).
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In vitro ubiquitylation was performed as recently
described (25). Brieﬂy, assays were performed in a 15ml
reaction volume in the presence of E1 activating enzyme
(0.7pmol), the indicated E2 conjugating enzymes
(9.5pmol) and ubiquitin (0.6pmol) or mutant ubiquitin
unable to form polyubiquitin chains (Boston Biochem,
Cambridge, USA) in buffer containing 25mM Tris–HCl
(pH 8.0), 4mM ATP, 5mM MgCl2, 200mM CaCl2,1m M
DTT, 10mM MG-132 for 1h at 30 C. SDS–PAGE sample
buffer 25mM Tris-HCl (pH 6.8), 2.5% beta-mercapto-
ethanol, 1% SDS, 5% glycerol, 1mM EDTA, 0.15mg/
ml bromophenol blue) was added, the samples were
heated for 5min at 95 C prior to separation of the
proteins on a 10% SDS–polyacrylamide gel, followed by
transfer to a PVDF membrane and immunoblot analysis
with the indicated antibodies.
Partial puriﬁcation of monoubiquitylated APE1
Whole-cell extracts from 20g HeLa cells was prepared as
described above and dialysed against Buffer A (50mM
Tris, pH 8.0, 1mM EDTA, 5% glycerol, 1mM DTT,
1mM PMSF) containing 150mM KCl and 1mM NEM.
The dialysate was clariﬁed by centrifugation at 25000rpm
for 20min at 4 C, ﬁltered through 0.45-mm ﬁlters and
fractionated by Phosphocellulose chromatography using
Buffer A containing 150mM KCl and 1mM NEM.
Proteins were eluted using Buffer A containing 1M KCl
and 1mM NEM, concentrated and diluted to 50mM
KCl and fractionated by Mono-Q chromatography and
the ﬂow-through was collected. Proteins were then
fractionated by Mono-S chromatography using Buffer A
containing 50mM KCl and proteins eluted using a linear
gradient of 50–1000mM KCl. Fractions were analysed by
10% SDS–PAGE and immunoblotting with APE1 or ubi-
quitin antibodies.
Mapping and identiﬁcation of ubiquitylation sites
Cleavage of the ﬁrst 35 amino acids from the APE1
protein for in vitro ubiquitylation assays was achieved by
treating APE1 (8mg) with 0.5mg of trypsin in buffer con-
taining 50mM Tris–HCl (pH 7.4), 50mM KCl, 10mM
MgCl2 and 1M urea for 2h at 23 C. APE1 was then
buffer exchanged three times using Amicon Ultra-4 ﬁlter
units (Millipore, Watford, UK) to remove trypsin and the
N-terminal tail of APE1, prior to incubation in the in vitro
ubiquitylation assay. For identiﬁcation of ubiquitylation
sites, full-length APE1 protein was ubiquitylated in vitro
using UbcH2 E2 conjugating enzyme as described above,
separated by SDS–PAGE and the Coomassie stained
band corresponding to monoubiquitylated APE1 was
excised, digested with trypsin and analysed by tandem
mass spectrometry as recently described (26).
Puriﬁcation of the E3 ubiquitin ligase for APE1
Cytoplasmic proteins were isolated from 20g HeLa cells
(Cilbiotech, Mons, Belgium) as described above and
dialysed against Buffer A (50mM Tris, pH 8.0, 1mM
EDTA, 5% glycerol, 1mM DTT, 1mM PMSF) contain-
ing 150mM KCl. The dialysate was clariﬁed by centrifu-
gation at 25000rpm for 20min at 4 C, ﬁltered through
0.45-mm ﬁlters and applied to a Phosphocellulose column
using Buffer A containing 150mM KCl and the ﬂow-
through was collected (PC-FI). PC-FI was concentrated
using Vivaﬂow 50 and 10kDa MWCO PES membrane
modules (Sartorius Stedim, Surrey, UK), diluted 2-fold
to achieve a ﬁnal concentration of 75-mM KCl in the
fraction and then added to a 20ml HiLoad Mono-Q
Sepharose column (GE Healthcare, Little Chalfont,
UK), washed with Buffer A containing 50mM KCl and
proteins eluted using a linear gradient from 50 to
1000mM KCl. Active fractions were pooled, concentrated
using Amicon Ultra-15 ﬁlter units (Millipore, Watford,
UK) and loaded onto a Superose-12 column (GE
Healthcare, Little Chalfont, UK) in Buffer A containing
150mM KCl. Active fractions were pooled, diluted to
50mM KCl and loaded onto a 1ml Mono Q HR 5/5
column (GE Healthcare, Little Chalfont, UK) in buffer
A containing 50mM KCl. Proteins were eluted using a
linear gradient of 50–1000mM KCl. At each chromatog-
raphy stage, aliquots of the fractions were analysed for E3
ubiquitin ligase activity using APE1 as a substrate and
active fractions pooled for the next chromatography
step. Active fractions from the ﬁnal Mono-Q chromatog-
raphy stage were analysed by tandem mass spectrometry
to identify candidate E3 ubiquitin ligases, as recently
described (26).
Plasmid transfection
Cells were transfected using Lipofectamine 2000 transfec-
tion reagent (Invitrogen, Paisley, UK) according to the
manufacturer’s protocol.
RT–PCR analysis
RNA was prepared from Ubr3 wild-type and knockout
MEFs using the RNeasy kit (Qiagen, Crawley, UK) and
cDNA was subsequently generated using the SuperScript
RT–PCR system (Invitrogen, Paisley, UK). UBR3, APE1
and actin was ampliﬁed using the following primers: 50-G
GGAATATTTGAACTTGATTTAATCTG-30 and 50-CC
ACACTGGACACGACTTCA-30;5 0-CGGGGAAGAAC
CCAAGTC-30 and 50-TCCTTCTCGGTTTTCTTT
GC-30;5 0-GGAGGGGGTTGAGGTGTT-30 and 50-TGT
GCACTTTTATTGGTCTCAAG-30, respectively.
Cycling conditions of one cycle at 95 C for 5min, 25
cycles (or 30 cycles for UBR3) at 95 C for 30s, 55 C for
20s and 72 C for 20s, and one cycle at 72 C for 5min.
PCR products were separated by 2% agarose gel electro-
phoresis containing SYBR Green (Invitrogen, Paisley,
UK) and analysed using the Molecular Imager FX
system (Bio-Rad, Hemel Hempstead, UK).
Clonogenic survival assay
Ubr3 wild-type and knockout MEFs were seeded in trip-
licate onto 10-cm
2 dishes at a density of 300cells/plate and
allowed to adhere for 16h. The cells were then treated
Nucleic AcidsResearch, 2012, Vol.40,No. 2 703with methyl methanesulphonate (MMS; Sigma-Aldrich,
Gillingham, UK) for 45min, the cells were washed twice
with PBS, the media replaced and the cells allowed to form
colonies over 7 days. Colonies were stained using methy-
lene blue and subsequently counted. The surviving
fraction was calculated by normalizing against the
colony numbers achieved for the untreated dishes.
Immunostaining
Subconﬂuent cell monolayers on coverslips were ﬁxed
with 4% paraformaldehyde for 30min at room tempera-
ture, the cells were permeabilized with 0.2% (w/v) Triton
X-100 for 10min at 4 C and blocked at room temperature
with 2% (w/v) BSA—Fraction V for 1h. The coverslips
were then incubated overnight at 4 C with primary
antibodies raised against APE1 or 53BP1 diluted 1:300
in BSA. The coverslips were washed and incubated in sec-
ondary antibodies, Alexa Fluor 488 F(ab0)2 fragment of
goat anti-rabbit or anti-mouse (Invitrogen, Paisley, UK)
for 1h. Slides were then mounted using Vectashield
hard set mounting media containing 4,6-diamidino-
2-phenylindole (DAPI; Vector Laboratories,
Peterborough, UK) and imaged using the BioRad MRC
600 confocal microscope and 488nm (FITC) argon laser
lines for excitation.
RESULTS
APE1 ubiquitylation in living cells
In HeLa cells, the concentration of APE1 protein is much
higher in the nucleus, although a substantial amount can
also be detected in the cytoplasm (Figure 1A). Taking into
account that the volume of the cytoplasm is  8-fold larger
than the volume of the nucleus, the absolute amount of
APE1 that can be extracted into cytoplasmic and nuclear
fractions is approximately the same (Figure 1B). To dem-
onstrate that APE1 ubiquitylation occurs in living cells,
we performed cell fractionation in the presence of
N-ethylmaleimide (NEM), which is an effective inhibitor
of deubiquitylation enzymes. We found that in HeLa cell
extracts prepared with NEM, in addition to APE itself,
immunoblotting with APE1-speciﬁc antibodies detected at
least three extra protein bands with a molecular weight of
between 45 and 60kDa, but these were only observed
in the cytoplasmic fraction (Figure 1B). Since the molecu-
lar weight of monoubiquitylated APE1 is expected
to be  44kDa, the protein with a molecular weight just
<50kDa that cross-reacted with the APE1 antibodies was
considered as a potential candidate for monoubiquitylated
APE1 (APE1ub, Figure 1B, indicated by arrow).
To provide evidence that this protein was APE1ub,w e
Figure 1. Puriﬁcation of ubiquitylated APE1 from human cells. (A) HeLa cells were ﬁxed and immunostained with DAPI and APE1 antibodies
demonstrating cytoplasmic and nuclear localization of APE1. (B) Cytoplasmic and nuclear fractions prepared from HeLa cells were analysed by 10%
SDS–PAGE and immunoblotting using the indicated antibodies. Three bands cross-reacting with APE1 antibodies, in addition to the 36kDa native
form of APE1, were present in the cytoplasmic fraction and were predicted to be ubiquitylated APE1. (C and D) Analysis of Mono-S chromatog-
raphy fractions puriﬁed from HeLa cells analysed by 10% SDS–PAGE and immunoblotting using either (C) APE1 or (D) ubiquitin antibodies.
(E) The peak monoubiquitylated APE1 containing Mono-S fraction (A9) was immunodepleted using APE1 antibodies and the pull-down was then
analysed by 10% SDS–PAGE and immunoblotting using either APE1 (left panel) or ubiquitin (right panel) antibodies. Molecular weight markers are
indicated on the left hand side of appropriate ﬁgures and the positions of monoubiquitylated APE1 (APE1ub) are shown.
704 Nucleic Acids Research, 2012,Vol. 40,No. 2partially puriﬁed this protein from a cytoplasmic extract
of HeLa cells by sequential Phosphocellulose, Mono-Q
and Mono-S chromatographies and monitored fractions
with APE1 antibodies. Fractions containing the
 44–50KDa protein cross-reacting with the APE1
antibodies were then probed with antibodies directed
against ubiquitin. We found that fractions containing
the  44–50kDa protein cross-reacted with both APE1
(Figure 1C) and ubiquitin (Figure 1D) speciﬁc antibodies.
Furthermore, after precipitation of this protein with APE1
antibodies, the precipitated protein still cross-reacted with
both APE1 and ubiquitin antibodies (Figure 1E). We thus
conclude that this  44-kDa protein is monoubiquitylated
APE1.
UBR3 is an E3 ubiquitin ligase for APE1
Having established that APE1 ubiquitylation occurs in
living cells, we pursued puriﬁcation of an E3 ubiquitin
ligase activity for APE1 from human cell extracts using
a series of chromatography columns (Figure 2A) and an
in vitro ubiquitylation assay. We ﬁrst observed that the
majority of APE1 E3 ubiquitin ligase activity was
detected in the cytoplasm (Figure 2B) and that the
activity became very pronounced after gel-ﬁltration over
a Superose 12 column (Figure 2C). From this column, we
determined that the E3 ubiquitin ligase for APE1 was
 200–400kDa. We further demonstrated that in vitro
ubiquitylation of recombinant APE1 is dependent on the
presence of both active fraction and ubiquitin (Figure 2D,
fourth lane) and further established, using wild-type and
mutant ubiquitin unable to form polyubiquitin chains,
that recombinant APE1 is polyubiquitylated since we
observed only a single product of ubiquitylation using
mutant ubiquitin (Figure 2D, last lane). We also
screened nine ubiquitin E2 conjugating enzymes for their
ability to mediate ubiquitylation of APE1 and discovered
that the ubiquitylation reaction is speciﬁc for UbcH2
(human homologue of yeast Ubc8, Figure 2E). Proteins
Figure 2. Puriﬁcation of the E3 ubiquitin ligase for APE1. (A) Puriﬁcation scheme for the isolation of the E3 ubiquitin ligase for APE1 from HeLa
cells. (B) Cytoplasmic and nuclear fractions (8mg) were prepared from HeLa cells and analysed for in vitro ubiquitylation activity for APE1
(2.8pmol) in the presence of E1 (0.7pmol), ubiquitin (0.6nmol) and various E2 enzymes (9.5pmol). Reactions were separated by 10% SDS–
PAGE and analysed by immunoblotting using APE1 antibodies. The major ubiquitylation activity against APE1 can be observed in the cytoplasmic
fraction. (C) In vitro ubiquitylation of APE1 (2.8pmol) by Superose 12 fractions puriﬁed from HeLa cells in the presence of E1 (0.7pmol), ubiquitin
(0.6nmol) and various E2 enzymes (9.5pmol). Reactions were separated by 10% SDS–PAGE and analysed by immunoblotting using APE1
antibodies. E3 ubiquitin ligase activity for APE1 corresponds to a protein of molecular weight between 200 and 400kDa. (D) In vitro ubiquitylation
of APE1 (2.8pmol) by an active fraction puriﬁed from HeLa cells in the presence of E1 (0.7pmol), various E2 enzymes (9.5pmol) and ubiquitin (Ub;
0.6nmol) or mutant ubiquitin (Mut-Ub) unable to form polyubiquitin chains. (E) In vitro ubiquitylation of APE1 (2.8pmol) by an active fraction
puriﬁed from HeLa cells in the presence of E1 (0.7pmol), ubiquitin (Ub; 0.6nmol) and various E2 enzymes (9.5pmol each). Reactions (D and E)
were separated by 10% SDS–PAGE and analysed by immunoblotting using APE1 antibodies. Molecular weight markers are indicated on the left
hand side of appropriate ﬁgures and the positions of ubiquitylated APE1 (APE1ub) are shown.
Nucleic AcidsResearch, 2012, Vol.40,No. 2 705from active fractions from the ﬁnal puriﬁcation step
(Mono-Q column) were subjected to nanoLC–MS/MS
tandem mass spectrometry, which revealed UBR3 as a
potential E3 ubiquitin ligase involved in UbcH2-
dependent APE1 ubiquitylation (Supplementary
Figure S1). Indeed, when active fractions were tested for
the presence of UBR3, we found a strong correlation
between APE1 ubiquitylation activity in these active frac-
tions (Figure 3A, upper panel) and the amount of UBR3
protein detected by immunoblotting (Figure 3A, lower
panel). To conﬁrm that UBR3 is responsible for APE1
ubiquitylation in the Mono-Q fractions, we immunopre-
cipitated UBR3 away from active fractions (Figure 3B,
lower panel) and demonstrated that UBR3-depleted
fractions had signiﬁcantly reduced ubiquitylation
activity (Figure 3B, upper panel). We next puriﬁed recom-
binant mouse UBR3 protein (Figure 3C) and found that
it was able to polyubiquitylate APE1 in an in vitro
ubiquitylation system reconstituted with puriﬁed
enzymes (Figure 3D).
It has recently been reported that Mdm2 is involved in
APE1 ubiquitylation (33). Although we found that
recombinant Mdm2 is able to ubiquitylate APE1 in an
in vitro ubiquitylation assay (Supplementary Figure S2),
we discovered that the major ubiquitylation activity for
APE1 puriﬁed from HeLa cells did not co-purify with
Mdm2 protein (Supplementary Figure S3). We thus
conclude that UBR3 is the major human E3 ubiquitin
ligase involved in polyubiquitylation of APE1.
UBR3 ubiquitylates several lysines at the N-terminus of
APE1
APE1 protein contains nine lysines within the 35 amino
acid N-terminal region (Figure 4A). To test whether these
residues are the sites of ubiquitylation, we cleaved off this
N-terminal region by controlled trypsin hydrolysis. We
demonstrated that in contrast to the full length protein
( 32% of the substrate is ubiquitylated), truncated
APE1 lacking the ﬁrst 35 amino acids from the
N-terminus cannot be efﬁciently ubiquitylated by a
UBR3-containing fraction puriﬁed from HeLa cells
( 4% of the substrate is ubiquitylated, Figure 4B). In
support of this ﬁnding, nanoLC–MS/MS tandem mass
spectrometry of in vitro ubiquitylated full length APE1
Figure 3. UBR3 is the E3 ubiquitin ligase for APE1. (A) In vitro ubiquitylation of APE1 (2.8pmol) by the ﬁnal Mono-Q chromatography fractions
puriﬁed from HeLa cells in the presence of E1 (0.7pmol), UbcH2 (10.5pmol) and ubiquitin (0.6nmol) were analysed by 10% SDS–PAGE and
immunoblotting using APE1 antibodies. Fractions containing APE1 ubiquitylation activity were shown to correlate with the presence of UBR3
protein detected by immunoblotting (lower panel). (B) The peak APE1 ubiquitylation activity containing fraction from the ﬁnal Mono-Q chroma-
tography was mock immunodepleted and immunodepleted with UBR3 antibodies. The fraction was subsequently analysed for in vitro ubiquitylation
of APE1 (2.8pmol) in the presence of E1 (0.7pmol), UbcH2 (10.5pmol) and ubiquitin (0.6nmol) by 10% SDS–PAGE and immunoblotting using
APE1 antibodies (upper panel). Furthermore, the pull-down was analysed by 10% SDS–PAGE and immunoblotting using UBR3 antibodies (lower
panel). (C) N-terminal Flag-tagged mouse UBR3 was expressed in S. cerevisiae, puriﬁed and analysed by 4–12% SDS–PAGE and Coomassie
staining. (D) Puriﬁed Flag-tagged mouse UBR3 was analysed for in vitro ubiquitylation of APE1 (2.8pmol) in the presence of E1 (0.7pmol),
UbcH2 (10.5pmol) and ubiquitin (0.6nmol) by 10% SDS–PAGE and immunoblotting using APE1 antibodies and UBR3 antibodies (lower
panel). Molecular weight markers are indicated on the left hand side of appropriate ﬁgures and the positions of ubiquitylated APE1 (APE1ub)
are shown.
706 Nucleic Acids Research, 2012,Vol. 40,No. 2identiﬁed lysines 7, 24, 25, 27, 32 and 35 as targets for
ubiquitylation. At least for an in vitro reaction, it seems
that these lysines are interchangeable ubiquitylation
targets for UBR3, since replacement of individual lysines
or combinations of two to three lysines with arginines did
not signiﬁcantly reduce ubiquitylation (Figure 4C). The
ubiquitylation of APE1 by UBR3 only signiﬁcantly
dropped when the majority of lysines (K24, K25, K27,
K31, K32 and K35) were replaced with arginines and
was completely abolished in the Lysine Less Mutant
(LLM), that was constructed by replacement of all but
K3 within the ﬁrst 35 amino acids of APE1 (Figure 4C,
last lane).
UBR3 knockout cells have increased levels of APE1 and
show genome instability
Ubr3-knockout mice have been generated and have
previously been shown to have a genetic
background-dependent lethality, indicating an essential
role for this gene (28). To assess the role of UBR3 in
controlling APE1 levels, we prepared cell extracts from
wild-type and Ubr3-knockout MEFs and found  2-fold
increase in APE1 levels in Ubr3-knockout cells (Figure
5A). To exclude that the increase in APE1 levels was
due to clonal variability, we further analysed two more
independent Ubr3-knockout cell lines in comparison to
three independent wild-type cell lines and found that the
Ubr3-knockout cells always contained higher APE1 levels
(Figure 5B). Interestingly, a cell line generated from a
Ubr3-heterozygous mouse also contained higher protein
levels of APE1 (Figure 5B). To further demonstrate that
APE1 stability depends on UBR3, we transfected plasmids
expressing mouse AP-endonuclease 1 (APEX) into
wild-type or Ubr3-knockout cells. The level of APEX ex-
pression was  5-fold higher in Ubr3-knockout cells
compared to wild-type cells (Figure 5C). RT–PCR of the
RNA puriﬁed from Ubr3-knockout cells clearly indicated
that the levels of ape1 mRNA in Ubr3-wild-type and
Ubr3-knockout cells is approximately the same
Figure 4. Identiﬁcation of UBR3 ubiquitylation sites within APE1. (A) Schematic diagram of the protein structure of APE1 showing the nuclear
localization sequences (NL1 and NL2), Ref-1 domain and nuclease domain. Major sites (K7/K24/K25/K27/K32/K35) of ubiquitylation by UBR3
identiﬁed by mass spectrometry are shown. (B) An N-terminal truncation of APE1 lacking the ﬁrst 35 amino acids (APE11-35) was analysed for
in vitro ubiquitylation, in comparison to full length protein (FL), by an active fraction puriﬁed from HeLa cells in the presence of E1 (0.7pmol),
UbcH2 (10.5pmol) and ubiquitin (0.6nmol) by 10% SDS–PAGE and immunoblotting using APE1 antibodies. (C) Wild-type protein (WT) and
APE1 mutants, in which the indicated lysines were mutated to arginines, were analysed for in vitro ubiquitylation by an active fraction puriﬁed from
HeLa cells in the presence of E1 (0.7pmol), UbcH2 (10.5pmol) and ubiquitin (0.6nmol) by 10% SDS–PAGE and immunoblotting using APE1
antibodies.
Nucleic AcidsResearch, 2012, Vol.40,No. 2 707(Figure 5D) and shows that modulation of APE1 is at the
protein level. These data were further conﬁrmed using
real-time PCR that showed only a 1.3±0.1-fold
increase in ape1 mRNA levels in Ubr3-knockout cells, in
contrast to an at least 2-fold increase in protein level
(Supplementary Figure S4).
We also noticed that the nuclei of Ubr3-knockout cells
have signiﬁcant variations in size and shape, in compari-
son to wild-type cells, that is an indicator of genetically
unstable cells (Figure 6A and B), (33). We hypothesized
that elevated levels of APE1 in Ubr3-knockout cells leads
to genomic instability through the imbalance of DNA
repair and the generation of excessive SSBs that in turn
will be converted into DNA double-strand breaks during
replication. In support of this hypothesis, we observed a
higher number of spontaneously formed 53BP1 foci
(Figure 6C and D), as well as higher levels of histone
H2AX phosphorylation in Ubr3-knockout cells
compared to wild-type cells (Figure 6E), indicating
increased levels of endogenously generated DNA
double-strand breaks. If our model is correct, then
over-expression of APE1 itself should generate DNA
strand breaks by misbalancing the repair of endogenous
DNA lesions. Indeed, over-expression of APE1 in HeLa
cells induced formation of DNA double-strand breaks as
detected by increased phosphorylation of histone H2AX
(Figure 6F). Imbalance of DNA repair in Ubr3-knockout
cells should also lead to increased formation of DNA
strand breaks after mutagen treatment and these can
then increase cell toxicity. Indeed, using clonogenic
survival assays we were able to show that Ubr3
knockout cells, in contrast to the wild-type cells, are
more susceptible to the cell killing effects of the DNA
alkylating agent MMS (Figure 6G), that generates base
lesions that are almost entirely dependent on APE1 for
their repair.
DISCUSSION
APE1 is an essential protein that possesses multiple
activities involved in DNA repair and it also operates as
a redox factor activating a number of transcription
factors, including NF-kB, AP-1 and p53 (34). Several
studies have addressed the transcriptional regulation of
APE1 however, it is also clear that post-translational
modiﬁcations of APE1 play a major role in protein
activity, stability and localization, although very little is
known about the mechanisms involved [reviewed in (35)].
In this study, we investigated the role of ubiquitylation
in the regulation of the steady state levels of APE1 protein
and identify both the E2 ubiquitin conjugating enzyme,
UbcH2 and the E3 ubiquitin ligase, UBR3, as the major
enzymes involved. Previously, it was suggested that
ubiquitylation of APE1 is accomplished by Mdm2 (32).
However, even though we found that Mdm2 can
ubiquitylate APE1 in vitro, we were not able to demon-
strate that Mdm2 puriﬁed from human cell extracts pos-
sessed a signiﬁcant ubiquitylation activity for APE1.
Nevertheless, we cannot completely rule out that Mdm2
may serve as a minor backup E3 ubiquitin ligase for APE1
in the absence of UBR3. There is also a possibility that
Mdm2, as a major regulator of p53, is involved in tran-
scriptional regulation of APE1 since p53 was implicated in
the negative regulation of APE1 transcription (36).
Figure 5. Cells from Ubr3-knockout mice contain elevated levels of APE1 protein. (A and B) Whole cell extracts from MEFs from several wild-type
(WT), Ubr3-knockout (KO) and heterozygous mice (HET) were prepared and analysed by 10% SDS–PAGE and immunoblotting using the indicated
antibodies (C) Wild-type and Ubr3-knockout MEFs cells were grown on 10-cm
2 dishes for 24h to 70–80% conﬂuency and then transfected with
equal amounts of mouse Flag-tagged APE1 (APEXFlag) expression plasmid. After 24h, cells were pelleted by centrifugation, whole cell extracts were
prepared and analysed by 10% SDS–PAGE and western blotting with the antibodies indicated. (D) RNA was prepared from wild-type and Ubr3-
knockout MEFs and the levels of APE1, UBR3 and actin mRNA analysed by RT–PCR.
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one of the ubiquitin ligase family members characterized
by the UBR box (28,29). The UBR box is a signature
unique to all known recognition E3 components (UBR1,
UBR2, UBR4 and UBR5) of the mammalian N-end rule
pathway, called N-recognins [reviewed in (37)]. The UBR
box of mouse UBR1 and UBR2 has been shown to
function as a substrate recognition domain required for
type-1 (basic; Arg, Lys and His) and type-2 (bulky hydro-
phobic; Phe, Tyr, Trp, Leu and Ile) destabilizing
N-terminal residues of the N-end rule pathway (29,38).
Although UBR3 shares several domains and sequence
similarities with UBR1 (25% identity, 51% similarity)
and UBR2 (25% identity, 48% similarity), UBR3 appar-
ently does not exhibit N-recognin activities, suggesting
that UBR3 may have a function outside the conventional
N-end rule pathway. However, very little is known about
its substrates and cellular functions. We now demonstrate
that UBR3 is involved in regulation of the steady state
levels of APE1 protein by ubiquitylating its N-terminal
lysines, thus stimulating its proteasomal degradation.
Since APE1 has the N-terminal Met-Pro-Lys sequence
and there is no evidence that APE1 is cleaved into a
C-terminal fragment bearing a destabilizing N-terminal
residue, it appears that UBR3 recognizes APE1 through
an alternative degradation signal.
In our studies to demonstrate the effect of
ubiquitylation on APE1, we used MEFs generated from
mice lacking exon 1 of Ubr3 and show that a loss of Ubr3
results in an increased level of APE1. We also show that
there is no increase in ape1 mRNA levels suggesting that
this difference in APE1 protein level is due to
post-translational regulation. It is still unclear whether ac-
cumulation of APE1 in Ubr3 knockout ﬁbroblasts is due
to a lack of mono- or polyubiquitylation, although based
on the in vitro ubiquitylation data the latter seems more
probable and since due to the very high stability of APE1
protein (turnover time >16h) neither cycloheximide nor
Figure 6. Cells from Ubr3-knockout mice are genetically instable. (A and C) MEFs from wild-type and Ubr3-knockout mice were ﬁxed and
immunostained with the indicated antibodies and stained with DAPI. (B) Graphic presentation of nuclei size distribution in wild-type and Ubr3-
knockout ﬁbroblasts (500 cell nuclei were evaluated). (D) Graphic representation of 53BP1 foci ratios calculated from three individual slides (53BP1
foci were counted from 100 cells/slide). (E) Whole-cell extracts from MEFs from wild-type (WT) and Ubr3-knockout (KO) mice were prepared and
analysed by 10% SDS–PAGE and immunoblotting using the indicated antibodies. (F) HeLa cells were grown on 10-cm
2 dishes for 24h to 70–80%
conﬂuency and then transfected with human Flag-tagged APE1 (APE1Flag) expression plasmid. After 24h cells were pelleted by centrifugation, whole
cell extracts were prepared and analysed by 10% SDS–PAGE and western blotting with the antibodies indicated. (G) MEFs from wild-type and
Ubr3-knockout mice were grown on 10-cm
2 dishes in triplicate and treated with the indicated concentrations of MMS for 45min and colonies
allowed to grow for 7 days. The graph represents the mean surviving fraction normalized against the untreated controls from three independent
experiments and the standard errors are shown.
Nucleic AcidsResearch, 2012, Vol.40,No. 2 709MG132 treatment experiments can be performed. In spite
of many attempts, we were also unable to transiently
over-express or efﬁciently knockdown UBR3 in mamma-
lian cells. Although the mechanism preventing UBR3
over-expression is unclear, most probably an excess of
UBR3 causes cell toxicity.
While common sense suggests that over-expression of
APE1 should result in faster DNA repair, recent data
from several laboratories indicates that an uncoordinated
increase in one of the repair enzymes of the base excision
repair (BER) pathway leads to misbalanced DNA repair
and genome instability (39). In the case of excessive APE1,
the repair intermediate that would accumulate would be
DNA SSBs that arise during BER of damaged DNA bases
or direct incision of abasic sites (5). If the amount of SSBs
generated by APE1 exceed the repair capacity of the sub-
sequent steps of BER (gap ﬁlling by DNA polymerase b
and DNA ligation by XRCC1–DNA ligase IIIa complex),
these SSBs can then be converted into DNA double-strand
breaks during replication. Accumulation of DNA
double-strand breaks may result in genomic instability
and increased susceptibility to the cell killing effects of
DNA damaging agents. The extent to which these events
occur would of course be dependent on the cell type
affected, since up-regulated downstream BER activity
may compensate for the effects of APE1 over-expression
and the ultimate effect on cellular survival is furthermore
dependent on the double-strand break repair capacity of
the affected cell. For the Ubr3-knockout cells, which
contain higher protein levels of APE1 than the corres-
ponding wild-type cells, we observed the hypothesized
effects. First, we found that Ubr3-knockout cells exhibit
a signiﬁcant variation in the size and shape of the nucleus,
that is a well-known hallmark of genomic instability (33).
We next demonstrated that Ubr3-knockout cells had a
higher number of spontaneous 53BP1 foci and increased
levels of gH2AX in response to endogenously generated
damage, both indicators for the presence of DNA
double-strand breaks (40). We show that this increase is
likely due to APE1 over-expression since transient
over-expression of APE1 in HeLa cells also show an
increase in the levels of gH2AX. Finally, we demonstrate
that Ubr3-knockout cells are more susceptible to the cell
killing effects of the DNA alkylating agent MMS, that
generates base damages which are almost entirely depend-
ent on APE1 for their repair.
It appears that precise tuning of the levels of DNA
repair enzymes involved in the BER pathway is required
for genome stability. Even a moderate misbalance of the
equilibrium between BER proteins may lead to accumu-
lation of DNA double-strand breaks and results in
genomic instability. This conclusion is supported by
previous observations that cell lines stably over-expressing
APE1 show genomic instability (41). Ubr3-knockout mice
were able to be generated depending on the genetic back-
ground, which results in early embryonic lethality or
neonatal lethality caused by a number of pathologies,
although the reason for this at that time remained
unclear (28). Our current study may partially explain the
observed phenotype of Ubr3-knockout mice and it is quite
possible that the different abilities of the 1239vImJ and
C57BL/6 mice, used to generate the Ubr3-knockout
mice, to tolerate DNA double-strand breaks may be one
of the reasons for the differential effects of the knockout.
In summary, we propose that newly synthesized cyto-
plasmic APE1 is directly transferred to the nucleus, where
it is able to participate in DNA repair. However if the level
of APE1 exceeds the amount required for DNA damage
repair, then APE1 is ubiquitylated by UBR3 and becomes
a target for proteasomal degradation. An important
question that remains unanswered is how cells would
know whether they need more or less APE1 and to
make the decision whether or not to ubiquitylate APE1.
In other words, how is the E3 ubiquitin ligase activity of
UBR3 on APE1 regulated? It is possible that other
post-translational modiﬁcations of APE1, including
recently reported phosphorylation (42) and acetylation
(43), may modulate its stability, activity or subcellular lo-
calization in response to DNA damage by controlling
UBR3 ubiquitylation and we are currently investigating
this hypothesis.
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